In research analyzing PD-L1 mRNA expression in EVs from NSCLC patients undergoing treatment with pembrolizumab and natalizumab, it was found that PD-L1 mRNA levels were notably higher in those who responded to treatment compared to those who did not, prior to the start of immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.